SCHEMBL3378723

SCHEMBL3378723

O=S(=O)(Nc1ccc(-c2ccc(F)c(Cl)c2)c(Cl)c1)C1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 5/20 0.45
FABP4 P15090 2/20 0.45
FABP5 Q01469 2/20 0.45
MAP2K4 P45985 1/20 0.42
PTGS2 P35354 4/20 0.42
PTGS1 P23219 2/20 0.42
DRD2 P14416 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
DRD3 P35462 1/20 0.42
HTR6 P50406 1/20 0.42
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
PKM P14618 2/20 0.41
EPHX2 P34913 1/20 0.40
NR1H4 Q96RI1 1/20 0.40
FABP3 P05413 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377083 0.81 PTGS2 (0.52) FABP4FABP5PTGS2PTGS1DRD2
SCHEMBL18422436 0.79 MAPT (0.43) DRD2HTR2AHTR2CDRD3HTR6
SCHEMBL3379334 0.78 KIF11 (0.46) KITMAP2K4EPHX2NR1H4
SCHEMBL3376000 0.77 PGR (0.46) MAPT
SCHEMBL3375807 0.76 DHODH (0.55) MAP2K4EPHX2NR1H4
SCHEMBL17803477 0.73 NPSR1 (0.47) MAPTMEN1ALDH1A1KMT2ALMNA
SCHEMBL3374747 0.73 KIF11 (0.51) KITPTGS2MAPTMEN1ALDH1A1
SCHEMBL3374738 0.72 MEN1 (0.51) MAPTMEN1ALDH1A1KMT2AEPHX2
SCHEMBL3378146 0.71 CYP17A1 (0.54) FABP4FABP5PTGS2PTGS1DRD2
SCHEMBL31679885 0.71 LMNA (0.53) FABP4FABP5TP53MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KIT 4087/4885FABP4 1067/4885FABP5 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.